Healthcare Global Enterprises Limited (HCG) announced its financial results for the second quarter and half-year ended September 30, 2026. The company reported a 16% year-on-year increase in revenue, reaching INR 7,318 million for Q2 FY27. Adjusted EBITDA saw a 17% rise to INR 1,425 million, with an improved margin of 19.7%. Key drivers included patient volume growth and a focus on high-complexity oncology treatments.
HCG Reports Strong Q2 FY27 Financial Performance
Healthcare Global Enterprises Limited (HCG), a prominent player in India’s cancer care network, has announced its financial results for the quarter and half-year ended September 30, 2026. The company demonstrated robust growth, with revenue from operations increasing by 16% year-on-year to INR 7,318 million for the second quarter of fiscal year 2027 (Q2 FY27).
Key Financial Highlights (Consolidated)
The consolidated results for Q2 FY27 reveal significant improvements:
-
Revenue from Operations grew by 15.8% YoY to INR 7,318 million, compared to INR 6,321 million in Q2 FY26.
-
Adjusted EBITDA increased by 17.2% YoY to INR 1,425 million, up from INR 1,215 million in Q2 FY26. The EBITDA margin improved by 51 basis points to 19.7%.
-
Profit Before Tax (PBT) before extraordinary items saw a substantial rise of 48.1% YoY, reaching INR 301 million.
-
Adjusted Profit After Tax (PAT), normalized for extraordinary items, was INR 192 million, reflecting a -9.3% YoY change, primarily due to a favourable one-time deferred tax adjustment in Q2 FY26.
CEO Commentary on Performance
Dr. Manish Mattoo, CEO of HealthCare Global Enterprises Ltd., commented on the results, stating, “We sustained our growth momentum in Q2 FY27, delivering revenue growth of 16% year-on-year to INR 7,318 million, driven by a 9% increase in patient volumes and a 7% improvement in average revenue per patient (ARPP). Adjusted EBITDA grew 17% year-on-year to INR 1,425 million, with a margin of 19.7%.” He further highlighted the focus on improving revenue mix, increasing contribution from high-complexity oncology treatments, and driving operational efficiencies.
Strategic Developments and Outlook
The company also highlighted key business developments for the quarter ending September 30, 2026, including capacity expansion with 25 operational beds added and the deployment of advanced technology such as the MR-LINAC system. HCG continues to focus on enhancing its clinical programs, including advanced cancer therapies and minimally invasive surgeries, alongside expanding its diagnostic capabilities.
HCG remains committed to delivering sustainable, profitable growth while broadening access to advanced, high-quality cancer care.
Source: BSE
